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Mitochondrial DNA has been used to investigate phylogenetic relationships and pathophysiologic roles in
aging, degenerative diseases, and cancer. We investigated the prognostic usefulness of mitochondrial DNA
minisatellite (mtMS) markers compared with nuclear short tandem repeat markers by evaluating
the laboratory performance and clinical value of these markers in a large sample of patients undergoing
allogeneic hematopoietic stem cell transplantation (allo-HSCT) with various simulated conditions in vitro and
in serial follow-up samples. We examined the value of mtMS markers as a prognostic indicator in 100 patients
with various hematologic disorders undergoing allo-HSCT, including 35 patients with longitudinal follow-up
for 55 months. The mtMS markers showed high sensitivity and accuracy for the quantitative detection
of chimerism compared with nuclear short tandem repeat markers, particularly in unrelated transplantation
and under inappropriate sampling conditions. Longitudinal follow-up after allo-HSCT disclosed that chime-
rism precisely reﬂected the status of engraftment or relapse during the clinicopathological course. Moreover,
changes in mtMS markers in recipients before allo-HSCT were associated with clinical outcomes. Our data
indicate that mtMS markers have multiple functions in monitoring mixed chimerism and predicting
prognosis after allo-HSCT.
Crown Copyright  2013 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow
Transplantation. All rights reserved.INTRODUCTION previously reported that mtDNA minisatellite (mtMS) mar-
Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is a crucial therapeutic modality for various
hematologic disorders [1,2]. Successful allo-HSCT requires
the engraftment of transplanted hematopoietic stem cells,
which reestablishes normal hematologic and immunologic
functions [3,4]. Therefore, reliable methods for monitoring
mixed chimerism (MC) in patients undergoing allo-HSCT
have been emphasized.
Nuclear short tandem repeat (STR) markers are widely
used for this purpose, because they are highly polymorphic
between individuals. The STR assay produces sensitive
quantitative results, with a detection limit of 1% to 3% using
ﬂuorescence-labeled primers and a capillary electrophoresis
system [5,6]. However, potential problems with the nuclear
STR assay include poor precision and relatively low sensi-
tivity, particularly when the target DNA content is low or
degraded [3].
Mitochondrial DNA (mtDNA) also has high variability and
numerous polymorphisms, which have been used to examine
personal identiﬁcation and phylogenetic relationships. Weedgments on page 924.
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03.002kers generally have higher sensitivity and accuracy compared
with nuclear STR markers [7,8]. These beneﬁcial attributes
have been applied only to small and limited sets of hemato-
logic disorders, however, which might not represent sufﬁ-
cient laboratory performance, especially in inappropriately
obtained specimens, or accurately reﬂect the clinical value
of mtMS markers in quantitatively determining MC after
allo-HSCT.
In the present study, we investigated the laboratory
performance and clinical value of mtMS markers compared
with nuclear STR markers in 100 patients undergoing
allo-HSCT, including serial follow-up samples and various
simulated conditions in vitro.
MATERIALS AND METHODS
Diagnostic and Therapeutic Characteristics of Patients
This study prospectively enrolled 100 patients (42 males and
58 females) with bone marrow (BM) failure and various hematologic
disorders who underwent allo-HSCT at Chonnam National University
Hwasun Hospital between August 2006 and February 2011. The study
was approved by the hospital’s Institutional Review Board. After patients
provided written informed consent, peripheral blood and BM samples
were collected. The transplantations comprised 88 HLA-matched and
12 HLA-mismatched cases, with 57 related donors and 43 unrelated donors.
The recipients ranged in age from 1 to 62 years. All had a malignant
hematologic disorder, which included aplastic anemia (n ¼ 17), myelodys-
plastic syndrome (MDS; n ¼ 15), acute myelogenous leukemia (n ¼ 23),
acute lymphoblastic leukemia (ALL; n ¼ 28), lymphoma (n ¼ 7), chronic
myelogenous leukemia (n ¼ 5), hemophagocytic lymphohistiocytosis
(n ¼ 4), and neuroblastoma (n ¼ 1). Patients’ diagnostic and therapeutic
characteristics are summarized in Supplemental Table S1.alf of American Society for Blood and Marrow Transplantation. All rights reserved.
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The study included patients receiving reduced-intensity or conventional
myeloablative conditioning before allo-HSCT. Conventional myeloablative
conditioning is deﬁned as standard high-dose radiotherapy or chemo-
therapy. Reduced-intensity conditioning is deﬁned as the use of ﬂudarabine
associated with low-dose total body irradiation (6 Gy) or busulfan (total
dose 8 mg/kg) or with other immunosuppressive or chemotherapeutic
drugs, such as melphalan or cyclophosphamide [9].
Preparation of Donor and Recipient Samples
Peripheral blood samples were obtained from the donor and recipient
before allo-HSCT for the selection of informative markers. BM samples
were usually obtained at 1, 2, 3, 6, 9, 12, 15, 18, and 24 months after
allo-HSCT, based on the clinical course. Cell preparation and total DNA
extraction were performed according to previously published protocols.
In brief, mononuclear cells collected from donor and recipient samples were
separated by density-gradient centrifugation and washed twice in PBS.
The ﬁnal PBS suspension contained 1  107 cells/mL. Total DNA was
extracted using the QIAamp Blood Mini Kits (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions and resuspended in TE buffer
(10 mM Tris-HCl and 1 mM EDTA; pH 8.0), then quantiﬁed spectrophoto-
metrically [8].
Chimerism Assay Using mtMS and Nuclear STR Markers
We chose 3 mtMS markersd303 poly C, 16184 poly C, and 514 (CA)
repeatdbased on our ﬁndings in a previous study [8]. We analyzed the
informativeness of the mtMS markers compared with nuclear STR markers
using clinical records. PCR ampliﬁcation and capillary electrophoresis for
nuclear STR and mtMS markers were performed following our published
protocols [8]. The markers’ nucleotide sequences are presented in
Supplemental Table S2.
In Vitro Mixing and Simulation Test to Determine the Sensitivity
and Accuracy of Nuclear STR and mtMS Markers
We performed an in vitro mixing test to determine the sensitivity and
accuracy of the mtMS and nuclear STR markers under various sample
conditions. Blood cells from the donor and recipient were mixed at various
ratios in donor cell proportions of 0.01, 0.03, 0.05, 0.1, 0.2, 0.3, and 0.5. The
sensitivity and accuracy of mtMS and nuclear STR markers were compared
in samples stored at room temperature (25C) and at 37C for 1, 2, 3, and 4
weeks.
Application of Both Markers to Serial Follow-Up Samples to Evaluate
Clinical Values
Clinicopathological parameters evaluated included WBC count, hemo-
globin (Hgb), platelet count, BM examination, and an MC assay using the
nuclear STR and mtMS markers. Thirty-ﬁve of the 100 enrolled patients
were followed longitudinally for clinical and pathological ﬁndings for up to
55 months (range, 3-55 months; median, 22 months).
Analysis of Clinical Characteristics According to Alteration Type
of mtMS Markers
Donors and recipients were classiﬁed based on the degree of sequence
alteration of mtMS markers. The complex type was deﬁned as the presence
of 3 or more copies in 303 poly C mtMS marker, and the simple type was
deﬁned as fewer than 3 copies. Clinicopathological parameters, including
overall survival (OS) and relapse-free survival (RFS), were analyzedTable 1
Informativeness of mtMS and Nuclear STR Markers
Marker Unrelated (n ¼ 43), n (%) Related
Nuclear STR
STR-D12S391 19 (44.2)* 18 (31.6
STR-D18S51 20 (46.5)y 29 (50.9
STR-F13A1 4 (9.3) 4 (7)
Amelogenin 0 (0) 2 (3.5)
STR-HUM FABP2 0 (0) 2 (3.5)
STR-HUM RENA-4 0 (0) 2 (3.5)
mtMS
303 poly C 30 (69.8)y 18 (31.6
16184 poly C 17 (39.5) 8 (14)
514 (CA) repeat 27 (62.8)* 8 (14)
* 514(CA) repeat versus D12S391; P ¼ .011.
y 303 poly C versus D18S51; P ¼ .001.
z 303 poly C versus D18S51; P ¼ .006.according to the simple or complex degree of alteration of the mtMSmarker
in both donor and recipient cells before allo-HSCT.
Statistical Analysis
The c2 test was used to determine statistical differences in informa-
tiveness between the mtMS and nuclear STR markers. Pearson’s correlation
coefﬁcient was used to determine the percent difference in quantiﬁed
chimerism in the mixing test. OS was deﬁned as the time between trans-
plantation and death from any cause, and RFS was deﬁned as the time
between transplantation and relapse or disease progression from under-
lying disease. RFS and OS were estimated by the Kaplan-Meier estimator.
Cox proportional hazards analysis was used to compare estimated hazard
ratios (HRs) and 95% conﬁdence intervals (CIs) for mortality and relapse in
patients according to the alteration type of mtMS from the donor and
recipient blood cells.
RESULTS
mtMS and Nuclear STR Markers Have Comparable
Discriminative Power in the Allo-HSCT Set
Informativeness was compared in the selected mtMS
markers and 6 nuclear STR markers (Table 1). The D18S51
and D12S391 markers were representative of informative
nuclear STR markers with high exclusion power, with
informativeness of 49% and 37%, respectively. The informa-
tiveness of the 303 poly C and 514(CA)repeat mtMS markers
was 48.5% and 35.0%, respectively. In particular, in the
unrelated allo-HSCT sample, the mtMS markers provided
greater discrimination than the nuclear STR markers: 69.8%
for 303 poly C and 62.8% for 514(CA)repeat versus 46.5%
for D18S51 and 44.2% for D12S391 (P ¼ .001 and .011).
In contrast, in related allo-HSCT, mtMS markers showed
lower discriminative power than those of the nuclear
markers: 50.9% for D18S51 versus 31.6% for 303 poly C (P ¼
.006). There were no statistically signiﬁcant differences
between the mtMS and nuclear STR markers in terms of
transplantation type (HLA-matched or -mismatched) or
source (Supplemental Tables S3 and S4).
mtMS Markers Have Greater Sensitivity and Accuracy
than Nuclear STR Markers in Inappropriately Stored
Samples
Sensitivity of the mtMS and nuclear STR markers was
assessed by an in vitro mixing test. Supplemental Figure 1
shows the formula used to calculate MC values. The mtMS
marker 303 poly C showed a detection limit of 1%, inde-
pendent of storage temperature and duration. The nuclear
STR marker D12S391 displayed a variable detection limit
exceeding 1%. In samples stored for longer than 3 weeks, the
D12S391 peakwas not observed, evenwith a high proportion
of donor cells (>10%). At room temperature, the calculated(n ¼ 57), n (%) Number/total Informativeness, %
) 37/100 37
)z 49/100 49
8/100 8
2/100 2
2/100 2
2/100 2
)z 48/99 48.5
25/85 29.4
35/100 35
Figure 1. Sensitivity and accuracy of 303 polyC mtMS marker compared with nuclear STR marker under different storage conditions. The 303 poly C showed
a constant 1% detection limit compared with the nuclear STR marker, which was independent of storage temperature and duration (A, B, C, and E). The nuclear
STR marker showed no peak or unstable results when samples were stored for more than 2 weeks at 37C (D), whereas the mtMS marker showed clear and precise
peaks (B).
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mixture ratio for up to 3 weeks of storage for both markers.
The nuclear STR marker showed no peak or unstable results
when samples were stored for longer than 2 weeks at 37C,
whereas the mtMS marker showed clear and precise peaks
(Figure 1).
mtMS and Nuclear STR Markers Show Comparable
Results in Evaluation of Chimerism Status
Data from follow-up analysis of quantitative chimerism
after allo-HSCT were available in 35 patients and showedFigure 2. Chimerism status examined by nuclear STR marker and mtMS marker in 3
Follow-up analysis of quantitative chimerism after allo-HSCT in 35 patients. The num
during the follow-up periods. The number next to the triangular symbols indicates th
by *) demonstrated discrepant chimerism results with the nuclear STR and mtMS ma
correlation of the mtMS marker.generally similar chimerism status with the 2 markers. The
concordancy for complete chimerism or MC in the 2 markers
was 95.1% (116 of 122 tests). Discrepancies in chimerism
status were evident in only 6 patients from the serial follow-
up samples (Figure 2A).
mtMS Markers Precisely Reﬂect Engraftment or Relapse
during the Clinicopathological Course
Among the 35 patients with follow-up data, 1 patient
(patient 15) who was diagnosed with hemophagocytic lym-
phohistiocytosis andunderwentunrelatedBMtransplantation5 patients and 2 representative examples with clinicopathological course. (A)
ber in parentheses after each patient result line indicates survival in months
e degree of MC (% of recipient cells) with each marker. Six patients (indicated
rkers. (B and C) Two representative examples (15 and 68) highlighting clinical
Table 2
Distribution and Clinicopathological Characteristics According to Alteration Type (Simple and Complex) of mtMS in Donors and Recipients
Characteristic Donor Recipient
Simple
(n ¼ 16)
Complex
(n ¼ 20)
P Value Simple
(n ¼ 20)
Complex
(n ¼ 16)
P Value
Age, yr, median (range) 25.88 (5-60) 32.5 (2-62) .308 31.15 (3-60) 27.56 (2-62) .583
Sex, n
Male 6 9 .65 7 8 .364
Female 10 11 13 8
Diagnosis, n
Aplastic anemia 5 3 .415 3 5 .30
ALL 2 8 5 5
Acute myelogenous leukemia 4 3 5 2
Chronic myelogenous leukemia 1 1 2 0
Hemophagocytic lymphohistiocytosis 1 1 1 1
Lymphoma 0 2 0 2
MDS 3 2 4 1
Donor type, n
Related 2 3 .829 0 5 .007
Unrelated 14 17 20 11
Transplantation type, n
BMT 6 5 .34 4 7 .402
UCBT 2 1 2 1
Haploidentical PBSCT þ UCBT 1 0 1 0
PBSCT 7 14 13 8
ABO matching status, n
Matched 7 8 .821 6 9 .112
Mismatched 9 12 14 7
HLA-matching status, n
Matched 12 17 .451 18 11 .109
Mismatched 4 3 2 5
Conditioning regimen, n
Conventional 4 6 .739 6 4 .739
Reduced-intensity 12 14 14 12
ANC >500/uL, day, median (range)* 16.44 (11-20) 15.33 (7-20) .358 15.45 (7-20) 16.43 (12-20) .423
Platelet count >20,000/uL, day, median (range)y 18.57 (10-43) 14.25 (5-26) .197 16.67 (5-43) 15.67 (8-26) .772
Graft-versus-host disease, n
Acute 0 2 .394 1 1 .979
Chronic 10 10 11 9
None 6 8 8 6
Engraftment, n
Delayed 10 12 .878 12 10 .878
Well engrafted 6 8 8 6
Chimerism status, n
Complete chimerism 12 16 .526 13 15 .02
MC 4 3 7 0
Survival status, n
Survived 13 13 .279 6 4 .739
Died 3 7 14 12
Relapse status, n
None 13 12 .169 6 5 .936
Relapsed 3 8 14 11
ANC indicates absolute neutrophil count; BMT, bone marrow transplantation; PBSCT, peripheral blood stem cell transplantation; UCBT, umbilical cord blood
transplantation.
* The day after allo-HSCT with an ANC >500/mL for 3 consecutive days.
y The day after allo-HSCT with a platelet count >20,000/mL for 3 consecutive days.
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clinicopathological data, including WBC, Hgb, platelet counts,
and BM study. Follow-up analysis revealed MC in approxi-
mately 40% to 60% of the donor cells using the nuclear STR
markers, without complete reﬂection of the clinicopath-
ological course but in approximately 30% to 70% of the donor
cells using the mtMS markers, which was compatible with
clinical improvement (Figure 2B).
Another patient (patient 68) who was diagnosed
with MDS and underwent unrelated peripheral blood stem
cell transplantation on February 25, 2010, achieved well-
engrafted status, with hypercellular marrow noted at the
initial BM study. A follow-up assay for MC found 100% donor
chimerism using the nuclear STR markers. However, the
mtMS markers showed MC with 2% to 3% remnant recipient
cells. Subsequently, a serial follow-up study using thenuclear STR markers showed 100% donor chimerism,
whereas the mtMS markers showed MC with 25.2% of the
donor cells. During this clinical stage, bicytopenia persisted,
and MDS ﬁnally recurred (Figure 2C). These ﬁndings indicate
that the mtMS markers can closely reﬂect engraftment or
relapse based on the clinicopathological course.
Patient Demographics and Characteristics According to
Alteration Type of mtMS Markers and Conditioning
Regimens for SCT
Patient demographic data according to mtMS alteration
type in donor and recipient are summarized in Table 2.
The simple and complex groups in both donor and recipient
mtMS were comparable with respect to age, sex, diagnosis,
donorerecipient relationship, type of transplantation,
pretransplantation conditioning regimens, and variable
Table 3
Multivariate Analysis of Relative Risk for Relapse and Death after Allo-HSCT
Relapse Death
HR (95% CI) P Value HR (95% CI) P Value
Conditioning regimen (conventional/reduced-intensity) 1.786 (1.019-3.129) .043 1.357 (0.727-2.534) .337
Donor mtMS type (complex/simple) 1.428 (0.777-2.624) .252 1.502 (0.777-2.903) .226
Recipient mtMS type (complex/simple) 1.069 (0.589-1.941) .825 0.68 (0.354-1.307) .248
Sex (male/female) 1.244 (0.926-1.671) .147 1.122 (0.816-1.542) .479
Reduced-intensity conditioning
Donor mtMS type (complex/simple) 1.496 (0.720-3.108) .28 1.41 (0.633-3.139) .40
Recipient mtMS type (complex/simple) 1.294 (0.632-2.648) .481 0.786 (0.358-1.728) .549
Sex (male/female) 1.201 (0.853-1.691) .294 0.986 (0.680-1.430) .941
Conventional conditioning
Donor mtMS type (complex/simple) 1.39 (0.708-2.726) .338 1.603 (0.779-3.300) .20
Recipient mtMS type (complex/simple) 0.90 (0.459-1.764) .759 0.622 (0.300-1.289) .201
Sex (male/female) 1.324 (0.939-1.868) .11 1.277 (0.881-1.852) .197
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conditioning regimen are also summarized in Supplemental
Table S5. The simple and complex groups were com-
parable in terms of all parameters except underlying
hematologic disorders.
Alteration Type of mtMS Markers in Recipient Cells before
Allo-HSCT Is Associated with Prognosis
Patients who received conditioning with a conventional
myeloablative regimen had a greater risk of relapse (relative
risk, 1.786; P ¼ .043) and lower OS and RFS (P ¼ .028)
compared with those who received a reduced-intensity
regimen (Table 3 and Supplemental Table S6). Patients
harboring BM cells with the simple type of mtMS markers
before allo-HSCT had shorter OS and RFS compared with
those with complex markers, especially in reduced-
intensity myeloablative regimens, but the difference was
not statistically signiﬁcant. Female recipients showed
a tendency toward shorter OS and RFS compared with male
recipients. Correlation with clinical outcome showed an
association between length heteroplasmy complexity ofFigure 3. Prognostic implications according to alteration type of mtMS marker before
cells before allo-HSCT showed shorter OS and RFS, albeit without statistical signiﬁcanc
in recipient BM cells before SCT disclosed worse prognosis (ie, shorter RFS) in patienmtMS markers from donor BM cells and a tendency toward
increased risk of relapse and overall mortality regardless of
the conditioning regimen (HR, 1.428; 95% CI, 0.777-2.624;
P ¼ .252 and HR, 1.502; 95% CI, 0.777-2.903, respectively;
P ¼ .226). Moreover, patients with acute leukemia, partic-
ularly ALL, harboring BM cells with the complex type of 303
poly C mtMS marker before allo-HSCT had shorter OS and
RFS compared with those with the simple type (P ¼ .041)
(Figure 3).
DISCUSSION
Monitoring the degree of engraftment is crucial to
distinguish between donor and residual host hematopoietic
cells in allo-HSCT, given that a quantitative determination
of MC can predict engraftment or graft rejection. Nuclear
STR markers have been widely used because of their high
polymorphism between individuals. A previous study re-
ported potential problems of the nuclear DNA STR markers,
however, including poor precision and relatively low sensi-
tivity, particularly in conditions involving lower content and
degradation of target DNA [3].allo-HSCT. (A and B) Complex type of 303 poly C mtMS marker from the donor
e. (C and D) Profound alteration (ie, complex type) of 303 poly C mtMS marker
ts with acute leukemia, especially ALL.
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performance and clinical values of mtMS markers compared
with nuclear STR markers in a series of 100 patients who
underwent allo-HSCT for various hematologic disorders,
including 35 patients with serial follow-up samples. Various
simulated conditions, including in vitro mixing and simu-
lated samples, were used to evaluate the laboratory perfor-
mance of the mtMS markers. The mtMS markers were also
applied to serial follow-up samples to evaluate the recipi-
ents’ clinical condition. The mtMS markers showed compa-
rable results as the nuclear STR markers in quantitative
monitoring of chimerism after allo-HSCT. Importantly, the
discriminative power of the mtMS markers was superior to
that of the nuclear STR markers in the unrelated allo-HSCT
sample. The mtMS markers also showed higher sensitivity
and accuracy than the nuclear STR markers in samples under
inappropriate storage conditions. The mtMS markers pre-
cisely reﬂected engraftment or relapse during the recipients’
clinicopathological course.
Sequence analysis of mtDNA is currently used in human
forensic identiﬁcation, especially in cases in which the
genomic DNA is highly degraded or nonexistent owing to
its abundance and inherent variability [10]. Hundreds to
thousands of mtDNA copies may exist in a single cell,
making recovery and sequencing easier compared with
a single copy of nuclear DNA per cell. In addition, the
haploid nature of mtDNA makes it easier to sequence than
diploid nuclear DNA [11], contributing to the preferential
ampliﬁcation and sequencing of mtDNA. Moreover, mtDNA
typing is used primarily in cases in which the nuclear DNA is
too degraded or cannot be recovered in sufﬁcient quantities.
These factors may explain the higher sensitivity and infor-
mativeness with mtMS markers compared with nuclear
DNA markers [8].
During the analysis of mtDNA hypervariable (HV) 1 and
HV2 sequences from Korean donors, we experienced great
difﬁculty in attempting to sequence beyond the poly-C
regions and assumed that this was likely related to
the high degree of length heteroplasmy in these donors [7].
In a previous study, we reported that all of our Korean
subjects displayed length heteroplasmies in both 303 poly C
and 16189 poly C regions in HV sequences. Marked sequence
variation of mtDNA in peripheral blood cells may originate
from mtDNA sequence heterogeneity of individual hemato-
poietic stem cells (CD34þ cells). Thus, mtDNA sequence
variations may provide a natural genetic marker for deter-
mining the contribution of individual stem cells to blood cell
production for the study of hematopoiesis and stem cell
trafﬁcking [12,13]. These observations regarding the high
degree of mtMS alteration prompted us to initiate the
present study.
The mtMSmarkers 303 poly C and 514(CA)repeat exhibited
sufﬁcient discriminative power, which were comparable
with D18S51 and D12S391 frequently used in clinical
samples. Although the performance of mtMS markers had
been demonstrated previously in small samples of hemato-
logic malignancy patients, it had not yet been evaluated
in large clinical samples. In particular, in the unrelated
allo-HSCT sample, mtMS markers provided a higher degree
of discrimination than nuclear STR markers; however, mtMS
markers showed lower discriminative power than the
nuclear STRmarkers in the related allo-HSCT sample. Overall,
mtMS markers were useful in clinical circumstances with an
increasing unrelated HSCT approach [14], although mtMS
markers had higher similarity in related donors than inunrelated donors, owing to the strictly maternal inheritance
of mtDNA.
In the in vitro mixing test, 303 poly C demonstrated
a detection limit of 1% independent of storage temperature
and duration. This ﬁndingmight be explained by the fact that
eukaryotic cells contain approximately 1000 mitochondria,
with 1 to 15 mtDNA molecules per mitochondrion, and thus,
a typical differentiated cell has approximately 1000-15,000
mtDNA copies. This abundant number of DNA copies makes
mtMS easier to recover and type than a single nuclear copy
per cell. In addition, the haploid form of mtDNA is more
readily sequenced than diploid nuclear DNA, which supports
preferential mtDNA ampliﬁcation and sequencing [8]. Both
markers were stable at room temperature for 3 weeks, but at
37C, the nuclear STR markers were unstable in samples
stored for longer than 2 weeks, whereas the mtMS markers
were stable. This ﬁnding has been explained in a previous
study of the imprecision of nuclear STRs with ranging from
5.4% for TPOX to 12% for D7S820 [11]. This low precision
mandates a careful approach, particularly in situations with
lower proportions of donor cells and various inappropriate
storage conditions. Overall, we found that the mtMSmarkers
had comparable discriminative power to nuclear STR
markers but more stable performance, even in inappropriate
storage conditions. The method and primer set might be
applicable to other populations besides Koreans. The mtMS
markers studied here should be screened when selecting
informative markers before allo-HSCT, given that the infor-
mativeness of each mtMS marker might differ in disparate
populations.
The mtMS markers studied here demonstrated excellent
clinical performance in addition with their in vitro perfor-
mance. Most follow-up data on quantitative chimerism
status were similar for the nuclear STR andmtMSmarkers. In
our follow-up analysis of 35 patients, mtMS marker status
closely reﬂected engraftment or relapse based on the clini-
copathological course.
Two representative examples among the 35 patients with
follow-up data are presented. One patient who had a good
prognosis with MC of approximately 40% to 60% using the
nuclear markers showed MC of approximately 30% to 70%
using the mtMS markers. Interestingly, the mtMS markers
reﬂected a positive tendency correlated with this patient’s
clinical course. Another patient who experienced a poor
clinical course had 100% donor chimerism with the nuclear
STR markers. In this patient, the mtMS markers provided
earlier evidence of relapse, with MC evident in 25.2% of
the donor cells, compared with the nuclear STR markers.
This indicates that mtMS markers can closely reﬂect
engraftment or relapse based on the clinicopathological
course.
The mitochondrion is a membrane-enclosed intracellular
organelle in most eukaryotic cells that provide most of
the cellular energy source and is involved in cell signaling,
cellular differentiation, and apoptosis, as well as in the
control of the cell cycle and cell growth. Comparing to
nuclear DNA, mtDNA has a 10 to 20 fold greater susceptibility
to genetic mutation, owing to its lack of intron and impaired
repair capacity. mtDNA aberrations have been linked to
aging, degenerative diseases, cancer, and autoimmunity.
Moreover, mtDNA alterations in either the number of mtDNA
copies or heteroplasmy have been related to pathogenesis in
various types of cancer [15,16].
Interestingly, the number of mtDNA copies from healthy
donors who demonstrated severe length alterations in the
E.J. Won et al. / Biol Blood Marrow Transplant 19 (2013) 918e924924303 poly C and also had 3 or more heteroplasmies exhibited
a two fold decrease in mtDNA copy number compared with
the number of copies isolated from donors with 2 peaks [7].
Thus, we postulate a possible relationship between the
degree of mtMS alteration and clinical outcome after
allo-HSCT.
Complex mtMS markers from donor BM cells indicated
a worse prognostic tendency, with increased relapse and
overall mortality, regardless of the pretransplantation
conditioning regimen. Moreover, patients with ALL with
complex type mtMS markers had shorter OS and RFS
compared with those with simple type markers (P ¼ .041).
This ﬁnding supports the idea that mtDNA aberrations,
including mtMS alterations, play a crucial role in tumori-
genesis as well as in disease progression, such as metastasis
[17]. mtDNA mutations and sequence heterogeneity are
frequently observed in leukemic cells, as well as in normal
blood/progenitor cells [18]. Our group previously reported
that normal blood cells, including BM microenvironments,
exhibit a profound alteration (complex heteroplasmy) of 303
poly C mtMS, resulting in an mtDNA replication defect [7].
Profound alteration of mtMS in recipient cells and micro-
environments may cause derangement of donor cell
engraftment andworse prognosis (marked by shorter OS and
RFS) after allo-HSCT.
Despite the aforementioned advantages of mtMS
markers, we note that the observed correlation between
the complexity of recipient mtDNA and transplantation
outcome is preliminary, and further investigation is required.
Furthermore, the universal application of mtDNA analysis
may be limited, because it is unlikely to be very useful in the
analysis of related transplantation chimerisms.
In conclusion, we report that the discriminative power of
the mtMS markers was comparable to that of the nuclear
DNA STR markers in our allo-HSCT sample. The mtMS
markers showed higher sensitivity and accuracy than those
of nuclear DNA STR markers in samples under inappropriate
storage conditions. Moreover, the mtMS markers precisely
reﬂected not only engraftment or relapse but also prognosis
after allo-HSCT.ACKNOWLEDGMENTS
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